Anxiety in women with lymphedema following treatment for breast cancer

Aim: The aim of the present study was to evaluate anxiety in women with lymphedema following treatment for breast cancer. Method: A cross-sectional study was conducted involving 32 consecutive patients with lymphedema stemming from breast cancer treatment. Women with lymphedema due to other causes were excluded. Anxiety was evaluated using the Beck Anxiety Inventory. Descriptive statistics were used for the analysis of events. Results: Among the 32 patients evaluated, 10 (31.25%) had a minimal level of anxiety, 10 (31.25%) had mild anxiety, seven (21.85%) has moderate anxiety and had mild to moderate depression and five (15.62%) had severe anxiety. Conclusion: In this study anxiety occurs in different degrees in women with lymphedema following treatment for breast cancer of moderate to severe anxiety.Introduction: The aim of the present study was to evaluate anxiety in women with lymphedema following treatmentfor breast cancer. Material and methods: A cross-sectional study was conducted involving 32 consecutive patients with lymphedemastemming from breast cancer treatment. Women with lymphedema due to other causes were excluded. Anxiety wasevaluated using the Beck Anxiety Inventory. Descriptive statistics were used for the analysis of events. Results: Among the 32 patients evaluated, 10 (31.25%) had a minimal level of anxiety, 10 (31.25%) had mild anxiety,seven (21.85%) has moderate anxiety and had mild to moderate depression and five (15.62%) had severe anxiety. Conclusions: In this study anxiety occurs in different degrees in women with lymphedema following treatment forbreast cancer of moderate to severe anxiety

Lymphatic therapy by godoy method in the treatment of dyspnea after Covid- 19: case report

Despite all efforts, this disease has been a major cause of mortality as well as sequelae after the infectious event. Issues regarding an effective form of treatment for the virus have led to efforts focused on the acute manifestations of the disease. The aim of the present study is to describe the first observational result of the treatment of a pulmonary sequela of COVID-19 with important symptomatic limitations. One month ago, the patient contracted COVID-19 and was treated clinically, but the case progressed with important respiratory and physical limitations. An increase occurred in the lymphedema and the patient sought treatment. She would waken at night with dyspnea and was unable to walk more than a few steps or climb stairs. Intensive treatment of the lymphedema was proposed using the Godoy Method®. The Godoy method for reversing fibrosis was useful in improving dyspnea in a short period of time in a patient with sequelae resulting from COVID-1

Adaptations in the Treatment of Congenital Lymphedema Centered on the Quality of Life

Case Description. This report describes the evolution, necessary adaptations, and complications in the treatment of a 9-year-old child with primary congenital lymphedema. Description of Intervention. The clinical treatment of lymphedema was started in the first year of the patient’s life and for five years she was only treated using the Godoy & Godoy technique of cervical stimulation. Three years ago the patient was prescribed a compression stocking made from a cotton-polyester fabric (grosgrain) because of a sudden increase in the lymphedema after she started to take growth hormones. Outcome and Conclusion. The combination of cervical stimulation and a compression stocking was effective to keep the child’s life relatively normal, performing all day-to-day and recreational activities

Intensive treatment of breast cancer-related lymphedema in patients with neurological injuries

The aim of this study is to report on the intensive treatment of lymphedema resulting from breast cancer therapy in a 51-year-old patient who experienced loss of muscle strength of the arm. This patient developed lymphedema after a mastectomy, axillary resection, chemotherapy and radiation therapy to treat breast cancer. When the patient arrived at the Clinica Godoy for treatment in August 2012, she was evaluated using bioimpedance and volumetry before and then every day during treatment. Intensive treatment was carried out for six hours per day on three consecutive days employing Manual Lymphatic Therapy, Mechanic Lymphatic therapy (RA Godoy®) and a grosgrain compression sleeve with daily adjustments to the size. In the initial physical examination the patient reported a score for the intensity of pain of 10 (Pain Scale), paresthesia in the entire arm and there was a 577 mL difference in volume due to edema compared to the contralateral limb. On Treatment Day 1 the paresthesia was reduced using the grosgrain sleeve and Mechanical Lymphatic Therapy; on Treatment Day 2, the pain had dropped to an intensity of 7 (Pain Scale); on Treatment Day 3, the pain decreased to an intensity of 5 (Pain Scale) and the difference in the volume of edema was only 193 mL. The patient returned home but followed the recommendations and treatment program used at the clinic. Monitoring was by routine assessments and guidance on the importance of using the grosgrain sleeve and Mechanical Lymphatic Therapy to maintain the results and prevent neurological damage.O objetivo do presente estudo é relatar o tratamento intensivo do linfedema, após câncer de mama, em paciente com perda da força muscular do membro. Relata-se o caso de uma paciente de 51 anos de idade, que evoluiu com linfedema pós-tratamento do câncer de mama, com mastectomia + esvaziamento axilar + quimioterapia e radioterapia. Após procurar a Clínica Godoy para tratamento em agosto de 2012, foi avaliada com a bioimpedância e volumetria inicial e diária. Realizou tratamento intensivo durante três dias consecutivos, por um período de 6 horas, com Terapia Linfática Manual, Terapia Linfática Mecânica (RA Godoy®) e uso de braçadeira de gorgorão, sendo feitos ajustes diários. Na avaliação inicial, apresentava dor de intensidade 10 (Escala de Dor), parestesia em todo o braço e uma diferença de volume total do edema de 577g em relação ao membro contra-lateral. No primeiro dia de tratamento obteve redução da parestesia com o uso da braçadeira de gorgorão e Terapia Linfática Mecânica; no segundo dia, a dor havia diminuído para a intensidade sete (Escala de Dor); no terceiro dia, a dor diminuiu para intensidade cinco (Escala de Dor) e a diferença de volume total do edema passou a ser de 193g. A paciente retornou para sua casa mantendo as mesmas recomendações e tratamento propostos na clínica. O acompanhamento é feito com avaliações de rotina e orientações sobre a importância do uso da braçadeira de gorgorão e drenagem linfática mecânica

Dominant inheritance and intra-familial variations in the association of Sturge-Weber and Klippel-Trenaunay-Weber syndromes

This case report shows a genealogical study where a woman has limb hypertrophy and her son has an association of Sturge-Weber syndrome with Klippel-Trenaunay-Weber syndrome. The Sturge-Weber and Klippel-Trenaunay-Weber syndromes appear to be different manifestations of the same affliction. Familial aggregation exists and transmission may be almost imperceptible between generations. Identification of minor manifestations may prove to be a valuable contribution to genetic counseling of families and the prevention of new cases

Comparison of reduction of edema after rest and after muscle exercises in treatment of chronic venous insufficiency

<p>Abstract</p> <p>Aim</p> <p>The aim of this work was to compare the reduction in edema obtained in the conservative treatment of phlebopathies after resting and after performing a muscle exercise program in the Trendelenburg position.</p> <p>Methods</p> <p>Twenty-eight limbs of 24 patients with venous edema of distinct etiologies and classified as between C3 and C5 using CEAP classification. Volumetric evaluation by water displacement was carried out before and after resting in the Trendelenburg position and after performing programmed muscle exercises 24 hours later under identical conditions of time, position and temperature. For the statistical analysis the paired t-test was used with an alpha error of 5% being considered acceptable.</p> <p>Results</p> <p>The average total volume of the lower limbs was 3,967.46 mL. The mean reduction in edema obtained after resting was 92.9 mL, and after exercises it was 135.4 mL, giving a statistically significant difference (p-value = 0.0007).</p> <p>Conclusion</p> <p>In conclusion, exercises are more efficient to reduce the edema of lower limbs than resting in the Trendelenburg position.</p

Correction of bifid nose with tongue-in-groove technique in patient with Tessier fissure 0-14

Madelung’s disease (MD) or Multiple Symmetric Lipomatosis is a condition characterized by the accumulation of unencapsulated adipose tissue deposited symmetrically around the neck and upper trunk (type I - most common form). Its etiology is still unclear, but it is clearly associated with chronic excessive consumption of alcoholic beverages. Physical deformities lead the patient to seek medical care, along with possible symptoms of cervical involvement such as reduced mobility and respiratory disorders. Multiple Symmetric Lipomatosis diagnosis is clinical and can be complemented with imaging to rule out other diagnostic hypotheses and assess the extent of involvement. Treatment can be performed in two ways: clinical or surgical (lipectomy or liposuction). We report the case of a patient with Multiple Symmetric Lipomatosis type I surgically treated with both techniques: cervical lipectomy and abdominal liposuction. The patient evolved satisfactorily, with a reduction in complaints and no recurrences so far

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to &lt;90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], &gt;300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of &lt;15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P&lt;0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P&lt;0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction &gt;0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease